Compare Hims and Hers Health Inc (HIMS) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs McCormick & Company, Incorporated — how do they compare? Hims and Hers Health Inc trades at $28.39 (market cap $6.55B), while McCormick & Company, Incorporated trades at $45.94 (market cap $12.39B). The key difference: McCormick & Company, Incorporated is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and McCormick & Company, Incorporated for 67 Days on average.
| HIMS | MKC | |
|---|---|---|
Market Cap | $6.55B | $12.39B |
Volume | 14,842,814 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $62.76 | $71.65 |
52-Week Low | $14.52 | $44.14 |
Typical Hold Time | 21 Days | 67 Days |
Enterprise Value | $7.25B | $17.07B |
Dividend Yield | — | 4.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
McCormick & Company (MKC) trades at $45.25, down 0.33% with a bearish technical signal despite strong Q3 2026 earnings that beat estimates. The stock shows attractive valuation metrics with a P/E of 8.18 and robust profitability including 19.39% net income margin. Recent performance reflects 17% sales growth driven by the Mexico acquisition and margin expansion, though technical indicators suggest near-term pressure with support at $44.
MKC presents a compelling value opportunity with below-sector P/E ratio and consistent dividend payments, though bearish technicals and mixed analyst sentiment (33% buy, 60% hold) indicate caution. Upside potential exists to the $53.50 consensus target, but investors face risks from integration challenges and macroeconomic pressure on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
